Related Experiment Video
Updated: Feb 15, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer
Yinghui Zhang1, Lynn Wester2, Jichao He2
1Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. y.zhang@lacdr.leidenuniv.nl.
Abstract:
Antiestrogen resistance in estrogen receptor positive (ER+) breast cancer is associated with increased expression and activity of insulin-like growth factor 1 receptor (IGF1R). Here, a kinome siRNA screen has identified 10 regulators of IGF1R-mediated antiestrogen with clinical significance. These include the tamoxifen resistance suppressors BMPR1B, CDK10, CDK5, EIF2AK1, and MAP2K5, and the tamoxifen resistance inducers CHEK1, PAK2, RPS6KC1, TTK, and TXK. The p21-activated kinase 2, PAK2, is the strongest resistance inducer. Silencing of the tamoxifen resistance inducing genes, particularly PAK2, attenuates IGF1R-mediated resistance to tamoxifen and fulvestrant. High expression of PAK2 in ER+ metastatic breast cancer patients is correlated with unfavorable outcome after first-line tamoxifen monotherapy. Phospho-proteomics has defined PAK2 and the PAK-interacting exchange factors PIXα/β as downstream targets of IGF1R signaling, which are independent from PI3K/ATK and MAPK/ERK pathways. PAK2 and PIXα/β modulate IGF1R signaling-driven cell scattering. Targeting PIXα/β entirely mimics the effect of PAK2 silencing on antiestrogen re-sensitization. These data indicate PAK2/PIX as an effector pathway in IGF1R-mediated antiestrogen resistance.
Insights
Insulin-like growth factor 1 receptor (IGF1R) drives antiestrogen resistance in ER-positive breast cancer. The p21-activated kinase 2 (PAK2) pathway is identified as a key driver, suggesting new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Antiestrogen resistance limits treatment efficacy in estrogen receptor-positive (ER+) breast cancer.
- Increased insulin-like growth factor 1 receptor (IGF1R) signaling is a known mechanism contributing to this resistance.
Purpose of the Study:
- To identify key regulators of IGF1R-mediated antiestrogen resistance using a kinome siRNA screen.
- To elucidate the role of identified regulators, particularly p21-activated kinase 2 (PAK2), in resistance mechanisms.
- To investigate the downstream signaling of IGF1R in the context of antiestrogen resistance.
Main Methods:
- Genome-wide kinome siRNA screen to identify regulators of IGF1R signaling.
- Gene silencing experiments (siRNA) to assess the impact of identified regulators on tamoxifen and fulvestrant resistance.
- Phospho-proteomics to define downstream signaling targets of IGF1R.
- Analysis of patient data correlating gene expression with clinical outcomes.
Main Results:
- A screen identified 10 regulators of IGF1R-mediated antiestrogen resistance, including suppressors and inducers.
- p21-activated kinase 2 (PAK2) was identified as the strongest resistance inducer; its silencing sensitized cells to antiestrogens.
- PAK2 and PAK-interacting exchange factors (PIXα/β) were identified as downstream IGF1R targets, independent of PI3K/Akt and MAPK/ERK pathways.
- High PAK2 expression in ER+ metastatic breast cancer patients correlated with poor outcomes after tamoxifen therapy.
Conclusions:
- The PAK2/PIX pathway is a critical effector in IGF1R-mediated antiestrogen resistance in ER+ breast cancer.
- Targeting PAK2 or PIX demonstrates potential for overcoming antiestrogen resistance.
- These findings highlight a novel therapeutic strategy for resistant ER+ breast cancer.
Related Concept Videos
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Resistivity
Resistance

